Department of Orthopaedics at the Warren Alpert Medical School of Brown University, Providence, RI, USA.
Clin Orthop Relat Res. 2024 Jan 1;482(1):175-181. doi: 10.1097/CORR.0000000000002744. Epub 2023 Jul 4.
Anabolic steroid use at supraphysiologic doses has been associated with an increased risk of tendon injury. However, the musculoskeletal effects of testosterone therapy in the clinical setting are not well understood.
QUESTIONS/PURPOSES: (1) Is prescription testosterone associated with a higher odds of subsequent quadriceps muscle or tendon injury? (2) Is prescription testosterone associated with a higher odds of surgical repair of the quadriceps tendon?
The PearlDiver Database, which contains data on Medicaid, Medicare, and commercially insured patients, allows for a large representative sample of the US population including both publicly and privately insured patients. The database was queried for all patients between 2011 and 2018 who filled a testosterone prescription. Additionally, all quadriceps injuries using ICD-9 and ICD-10 codes between 2011 and 2018 were queried. Propensity score matching based on age, sex, Charlson comorbidity index, and specific comorbidities allowed us to create matched control groups. We used the t-test and chi-square analysis to compare the unmatched and matched cohorts. A total of 151,797 patients (123,627 male patients and 28,170 female patients) with a history of filled testosterone prescriptions were included in the study after matching with the control group, which was of equal size and representation of age, male-female proportions, and comorbidities. Chi-square and logistic regression analyses were performed to compare odds of quadriceps injury and quadriceps tendon repair among the testosterone groups to that of their respective control groups by age and sex.
Within 1 year of filling prescriptions for testosterone, 0.06% (97 of 151,797) of patients experienced a quadriceps injury compared with less than 0.01% (18 of 151,797) of patients in the control group (OR 5.4 [95% CI 3.4 to 9.2]; p < 0.001). Within the sex-specific matched groups, filling a testosterone prescription was associated with an increase in the odds of quadriceps injury in male patients within 1 year of the prescription (OR 5.8 [95% CI 3.5 to 10.3]; p < 0.001). Additionally, patients who filled a testosterone prescription were at increased risk of having quadriceps tendon repair within a year of the injury than were patients in the matched control group (OR 4.7 [95% CI 2.0 to 13.8]; p = 0.001).
Considering these findings, it is important for physicians to counsel patients receiving testosterone replacement therapy of the substantially increased odds of quadriceps tendon injury. Future investigations into the mechanisms of influence of exogenous anabolic steroids on tendon injury remains of interest.
Level III, therapeutic study.
在高于生理剂量下使用合成代谢类固醇会增加肌腱损伤的风险。然而,在临床环境中,睾丸激素治疗的肌肉骨骼影响尚不清楚。
问题/目的:(1)处方睾丸激素是否与随后的股四头肌肌肉或肌腱损伤的几率增加有关?(2)处方睾丸激素是否与股四头肌腱修复的几率增加有关?
PearlDiver 数据库包含关于医疗补助、医疗保险和商业保险患者的数据,允许对包括公共和私人保险患者在内的美国人口进行大量有代表性的抽样。该数据库对 2011 年至 2018 年间服用睾丸激素处方的所有患者进行了查询。此外,还对 2011 年至 2018 年间使用 ICD-9 和 ICD-10 代码的所有股四头肌损伤进行了查询。基于年龄、性别、Charlson 合并症指数和特定合并症的倾向评分匹配允许我们创建匹配的对照组。我们使用 t 检验和卡方分析比较了未匹配和匹配的队列。在与对照组匹配后,共有 151797 名(123627 名男性患者和 28170 名女性患者)有历史记录的睾丸激素处方患者被纳入研究,对照组的大小和年龄、男女比例和合并症的代表性相同。卡方和逻辑回归分析用于比较睾丸激素组与各自对照组之间股四头肌损伤和股四头肌腱修复的几率,按年龄和性别进行比较。
在服用睾丸激素处方后的 1 年内,0.06%(151797 名患者中的 97 名)的患者发生股四头肌损伤,而对照组中不到 0.01%(151797 名患者中的 18 名)(OR 5.4 [95% CI 3.4 至 9.2];p < 0.001)。在性别特异性匹配组中,在处方后的 1 年内,服用睾丸激素与男性患者股四头肌损伤几率增加相关(OR 5.8 [95% CI 3.5 至 10.3];p < 0.001)。此外,与匹配对照组相比,服用睾丸激素的患者在受伤后一年内接受股四头肌腱修复的风险增加(OR 4.7 [95% CI 2.0 至 13.8];p = 0.001)。
鉴于这些发现,医生有必要告知接受睾丸激素替代治疗的患者股四头肌腱损伤的几率大大增加。对外源性合成代谢类固醇对肌腱损伤影响机制的进一步研究仍然很有意义。
III 级,治疗研究。